Tag Archives: Almirall

Almirall arbeitet mit Ablexis und AlivaMab Discovery Services zusammen, um seine Entwicklungsbemühungen für innovative Behandlungsoptionen für Patienten mit schweren Hauterkrankungen zu beschleunigen

Durch diese Lizenzvereinbarung mit Ablexis erhält Almirall Rechte zur Nutzung der AlivaMab®-Maustechnologie für die Forschung, Entwicklung und Vermarktung von Antikörpern AlivaMab Mouse bietet hochmoderne transgene Mausplattformen, die humane therapeutische Antikörper mit hoher Vielfalt liefern Almirall wird mit AlivaMab Discovery Services … Read the full press release

Almirall partners with Ablexis and AlivaMab Discovery Services to accelerate its development efforts for innovative treatment options for patients suffering from severe skin diseases

Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and commercialisation of antibodies AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering highdiversity human therapeutic antibodies Almirall will partner with AlivaMab … Read the full press release

Almirall’s open innovation platform AlmirallShare announces two new partnerships aimed at finding new ways for the treatment of skin cancer and atopic dermatitis

These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim to identify new biosignatures and treatments for skin cancer and atopic dermatitis AlmirallShare is responsible for 50% of the private-public … Read the full press release

On World COPD Day 2013 physicians and experts emphasize importance of 24hour symptoms relief of Chronic Obstructive Pulmonary Disease (COPD) sufferers

Most of the 64 million COPD patients around the world, including over 2 million in Spain, must contend with breathlessness, excessive mucus, chronic cough and other debilitating symptoms throughout  24hours a day The World Health Organization estimates that COPD kills … Read the full press release

Spanish pharmaceutical company Almirall released its H1 2013 financial results

Barcelona,  05-8-2013 — /EuropaWire/ — Almirall’s H1: Executing on growth platforms, financial delivery on track Financial performance in line with guidance Aclidinium now available in 13 countries with five new launches planned before year’s end US/EU filings of aclidinium/formoterol combination are … Read the full press release